Valeant Pharmaceuticals

VRX-T

Analysis and Opinions about VRX-T

Signal
Opinion
Expert
BUY
BUY
June 26, 2018

We’re dealing with the ashes of the former company. They’re going to change their name. His model priced is $33.48 (US $) which is 45% higher than the current price. The stock has major volatility. He likes this space (he also holds TEVA and Endo International) because it has been crushed.

We’re dealing with the ashes of the former company. They’re going to change their name. His model priced is $33.48 (US $) which is 45% higher than the current price. The stock has major volatility. He likes this space (he also holds TEVA and Endo International) because it has been crushed.

Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$31.050
Owned
Yes
DON'T BUY
DON'T BUY
June 12, 2018

This is the Lazarus story of 2018, back from the dead. They are not anyones favorite stock. Even though they have sold off a lot of assets, they still have a lot of debt on their balance sheet and he called their profitability dubious, going forward. They have cleaned up a lot of their mess but they have a long way to go before becoming the kind of stock that he would consider for his type of portfolio. The debt burden in a rising interest rate environment, with many maturities that must be rolled over, poses too much risk.

This is the Lazarus story of 2018, back from the dead. They are not anyones favorite stock. Even though they have sold off a lot of assets, they still have a lot of debt on their balance sheet and he called their profitability dubious, going forward. They have cleaned up a lot of their mess but they have a long way to go before becoming the kind of stock that he would consider for his type of portfolio. The debt burden in a rising interest rate environment, with many maturities that must be rolled over, poses too much risk.

David Baskin
President, Baskin Wealth Management
Price
$34.650
Owned
No
DON'T BUY
DON'T BUY
February 27, 2018

The stock is no longer hot and still has problems but they are moving in the right direction: selling off assets, paying down debt, but the financial statements are still horrific. Revenues are coming down and the debt load is huge. If it finally turns, though, it is so well followed that it could have a real run to the upside. It is difficult to figure out short term price points for this stock.

The stock is no longer hot and still has problems but they are moving in the right direction: selling off assets, paying down debt, but the financial statements are still horrific. Revenues are coming down and the debt load is huge. If it finally turns, though, it is so well followed that it could have a real run to the upside. It is difficult to figure out short term price points for this stock.

Benj Gallander
President, Contra the Heard Investment Letter
Price
$23.750
Owned
Unknown
DON'T BUY
DON'T BUY
February 26, 2018

He would look for a different one to consider buying. It is complicated, more so than other pharmas. It has a lot of debt, there are regulatory issues, and governments are trying to push down the price of drugs. He might own JNJ-N because they have enough bets in enough places.

He would look for a different one to consider buying. It is complicated, more so than other pharmas. It has a lot of debt, there are regulatory issues, and governments are trying to push down the price of drugs. He might own JNJ-N because they have enough bets in enough places.

Teal Linde
Portfolio Manager & Publisher, Linde Equity Report, Linde Equity Report
Price
$23.920
Owned
Unknown
DON'T BUY
DON'T BUY
January 23, 2018

This is in the category of "too tough to figure out". There are so many moving parts. The business is in a de-leveraging state where they are trying to sell off assets from years of the acquisition binge to pay down debt. The new CEO has been pretty aggressive in selling off assets, trying to raise cash. It still has a lot of financial leverage, and is very hard to analyse. There are better ways to make money.

This is in the category of "too tough to figure out". There are so many moving parts. The business is in a de-leveraging state where they are trying to sell off assets from years of the acquisition binge to pay down debt. The new CEO has been pretty aggressive in selling off assets, trying to raise cash. It still has a lot of financial leverage, and is very hard to analyse. There are better ways to make money.

Colin Stewart
CEO & Portfolio manager, JC Clark Investments Ltd.
Price
$27.710
Owned
No
DON'T BUY
DON'T BUY
January 17, 2018

Their biggest challenge is restructuring, which previous management took up on a manic hike and drove off a cliff, and has left the company saddled with $27 billion of debt. The challenge for new management is to shed assets without shedding all the associated profitability. They are having some success having divested some assets. The problem is that a lot of the EBITDA is evaporating along with those asset divestitures. The bond market is taking a bit more constructive look at the company, although the credit rating is still deeply entrenched in the junk category. This is trading at 6X earnings, which tells you the market is deeply sceptical that they are going to achieve the consensus earnings forecasts this year. It's very much a show me story. He would steer clear.

Their biggest challenge is restructuring, which previous management took up on a manic hike and drove off a cliff, and has left the company saddled with $27 billion of debt. The challenge for new management is to shed assets without shedding all the associated profitability. They are having some success having divested some assets. The problem is that a lot of the EBITDA is evaporating along with those asset divestitures. The bond market is taking a bit more constructive look at the company, although the credit rating is still deeply entrenched in the junk category. This is trading at 6X earnings, which tells you the market is deeply sceptical that they are going to achieve the consensus earnings forecasts this year. It's very much a show me story. He would steer clear.

Brian Madden
Senior VP & Portfolio Manager, Goodreid Investment Council
Price
$28.250
Owned
No
DON'T BUY
DON'T BUY
January 10, 2018

Although a lot of the bad news, drama and carnage is behind it, he wouldn't be a buyer. There isn't any clarity on how they are going to make money in the future. It’s difficult to see a clear path to profits and growth in those profits.

Although a lot of the bad news, drama and carnage is behind it, he wouldn't be a buyer. There isn't any clarity on how they are going to make money in the future. It’s difficult to see a clear path to profits and growth in those profits.

Kash Pashootan
CEO & Chief Investment Officer, First Avenue Investment Counsel
Price
$29.480
Owned
Unknown
COMMENT
COMMENT
December 14, 2017

He’s always very cautious with fallen angels. It almost takes a miracle to bring them back to life. The company has a huge debt. They still have some assets that are worthwhile, but are trying to work their way out of a very difficult situation. A long, hard road ahead before this company gets out of the woods.

He’s always very cautious with fallen angels. It almost takes a miracle to bring them back to life. The company has a huge debt. They still have some assets that are worthwhile, but are trying to work their way out of a very difficult situation. A long, hard road ahead before this company gets out of the woods.

David Cockfield
Managing Director, Northland Wealth Management
Price
$25.110
Owned
Unknown
COMMENT
COMMENT
December 12, 2017

Has never been an owner of this. The stock had a nice bounce, but she still would not be a buyer. They've sold off some drugs, refinanced and pushed back some of the maturities on their debt, and thinks this is part of the reason why the stock has moved. It needs clarity on where they are going to get their future growth.

Has never been an owner of this. The stock had a nice bounce, but she still would not be a buyer. They've sold off some drugs, refinanced and pushed back some of the maturities on their debt, and thinks this is part of the reason why the stock has moved. It needs clarity on where they are going to get their future growth.

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$28.180
Owned
No
SPECULATIVE BUY
SPECULATIVE BUY
December 11, 2017

This is kicking around the $20 range. It has picked up recently, along with the entire pharmaceutical industry. Instead of being “extremely speculative” he would call it just “speculative” at this stage.

This is kicking around the $20 range. It has picked up recently, along with the entire pharmaceutical industry. Instead of being “extremely speculative” he would call it just “speculative” at this stage.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$26.450
Owned
No
COMMENT
COMMENT
December 8, 2017

The Dimension Fund (contrarian investors) has been buying to add to their position. When they buy into a company, that is a good sign for a lot of investors. This company has been a fascinating topic of conversation over the past few years. They were doing too many takeovers and taking on way too much debt. Still has a big debt load, but have been paying it off and he can see how this could be a good turnaround play. Because of their debt, there are still dangers out there.

The Dimension Fund (contrarian investors) has been buying to add to their position. When they buy into a company, that is a good sign for a lot of investors. This company has been a fascinating topic of conversation over the past few years. They were doing too many takeovers and taking on way too much debt. Still has a big debt load, but have been paying it off and he can see how this could be a good turnaround play. Because of their debt, there are still dangers out there.

Benj Gallander
President, Contra the Heard Investment Letter
Price
$25.360
Owned
Unknown
DON'T BUY
DON'T BUY
December 1, 2017

He is concerned about the debt they have carried and the legacy of it. Management has done a good job of paying it down and refocusing the company, but a lot of people are looking at the price of 3 years ago and it is not getting back there. He does not own any but is looking at JNJ-N and GILD-Q.

He is concerned about the debt they have carried and the legacy of it. Management has done a good job of paying it down and refocusing the company, but a lot of people are looking at the price of 3 years ago and it is not getting back there. He does not own any but is looking at JNJ-N and GILD-Q.

Lyle Stein
Sr. Portfolio & Managing Director, Vestcap Investment Management
Price
$21.920
Owned
No
WAIT
WAIT
December 1, 2017

It topped mid-2015 and drifted. Does seems to be having some resistance around $22. If it breaks above 22-23$ and stays above for a few days, it might be worth buying. But buying here might reverse back down at the bottom of the trading pattern.

It topped mid-2015 and drifted. Does seems to be having some resistance around $22. If it breaks above 22-23$ and stays above for a few days, it might be worth buying. But buying here might reverse back down at the bottom of the trading pattern.

Keith Richards
Portfolio Manager, ValueTrend Wealth Management
Price
$21.920
Owned
Unknown
DON'T BUY
DON'T BUY
November 30, 2017

It has been better than over the last couple of years. The valuation is cheap but there are a lot of headwinds with this company. There is a heavy debt load. Despite the long base it is building he is still staying on the sidelines. You want to stay with the better quality names. You want to stay away from most of that group.

It has been better than over the last couple of years. The valuation is cheap but there are a lot of headwinds with this company. There is a heavy debt load. Despite the long base it is building he is still staying on the sidelines. You want to stay with the better quality names. You want to stay away from most of that group.

Don Lato
President, Padlock Investment Management
Price
$21.730
Owned
No
DON'T BUY
DON'T BUY
November 17, 2017

A really tough one, but chart shows it has a base at around the current price. The longer this goes at that price, the better it is for the stock. Healthcare is reasonable in this secular bull market. Until this gets above $25 it’s just too volatile. Anything between now and $25 might be better for a shorter-term trader.

A really tough one, but chart shows it has a base at around the current price. The longer this goes at that price, the better it is for the stock. Healthcare is reasonable in this secular bull market. Until this gets above $25 it’s just too volatile. Anything between now and $25 might be better for a shorter-term trader.

Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$18.800
Owned
Unknown
Showing 1 to 15 of 714 entries